about
Complex links between natural tuberculosis and porcine circovirus type 2 infection in wild boar.Comparison of four lung scoring systems for the assessment of the pathological outcomes derived from Actinobacillus pleuropneumoniae experimental infectionsPotential use of local and systemic humoral immune response parameters to forecast Mycoplasma hyopneumoniae associated lung lesions.Control of Mycoplasma hyopneumoniae infections in pigs.Current perspectives on the diagnosis and epidemiology of Mycoplasma hyopneumoniae infection.Evaluation of natural porcine circovirus type 2 (PCV2) subclinical infection and seroconversion dynamics in piglets vaccinated at different ages.Exploratory study on the transcriptional profile of pigs subclinically infected with porcine circovirus type 2.Determinants for swine mycoplasmal pneumonia reproduction under experimental conditions: A systematic review and recursive partitioning analysis.Assessment of Mycoplasma hyopneumoniae-induced Pneumonia using Different Lung Lesion Scoring Systems: a Comparative Review.Pigs naturally exposed to porcine circovirus type 2 (PCV2) generate antibody responses capable to neutralise PCV2 isolates of different genotypes and geographic origins.Update on Mycoplasma hyopneumoniae infections in pigs: Knowledge gaps for improved disease control.Induction of mycoplasmal pneumonia in experimentally infected pigs by means of different inoculation routes.Effect of high and low levels of maternally derived antibodies on porcine circovirus type 2 (PCV2) infection dynamics and production parameters in PCV2 vaccinated pigs under field conditions.Virological and serological characterization of vaccinated and non-vaccinated piglet subpopulations coming from vaccinated and non-vaccinated sows.Effect of porcine circovirus type 2 (PCV2) load in serum on average daily weight gain during the postweaning period.Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae.Comparison of the immunoperoxidase monolayer assay and three commercial ELISAs for detection of antibodies against porcine circovirus type 2.Can Porcine circovirus type 2 (PCV2) infection be eradicated by mass vaccination?Dynamics of Mycoplasma hyopneumoniae infection in 12 farms with different production systems.Experimental infection of pigs with Border disease virus isolated from Pyrenean chamois (Rupicapra pyrenaica).Torque teno sus virus 1 and 2 viral loads in postweaning multisystemic wasting syndrome (PMWS) and porcine dermatitis and nephropathy syndrome (PDNS) affected pigs.Prevalence of swine Torque teno virus in post-weaning multisystemic wasting syndrome (PMWS)-affected and non-PMWS-affected pigs in Spain.Use of a polymerase chain reaction assay and an ELISA to monitor porcine circovirus type 2 infection in pigs from farms with and without postweaning multisystemic wasting syndrome.Genotypic shift of porcine circovirus type 2 from PCV-2a to PCV-2b in Spain from 1985 to 2008.Theoretical and experimental approaches to estimate the usefulness of pooled serum samples for the diagnosis of postweaning multisystemic wasting syndrome.Subclinical porcine circovirus type 2 infection does not modulate the immune response to an Aujeszky's disease virus vaccine.Lack of effect of piglet vaccination against Porcine circovirus type 2 (PCV2) on serum viral loads of Torque teno sus virus 2 (TTSuV2).Torque teno virus (TTV) infection in sows and suckling piglets.Retrospective study on swine Torque teno virus genogroups 1 and 2 infection from 1985 to 2005 in Spain.Torque teno virus (TTV) is highly prevalent in the European wild boar (Sus scrofa).Quantification of porcine circovirus type 2 (PCV2) DNA in serum and tonsillar, nasal, tracheo-bronchial, urinary and faecal swabs of pigs with and without postweaning multisystemic wasting syndrome (PMWS).Lack of an effect of a commercial vaccine adjuvant on the development of postweaning multisystemic wasting syndrome (PMWS) in porcine circovirus type 2 (PCV2) experimentally infected conventional pigs.Association between Mycoplasma hyopneumoniae at different respiratory sites and presence of histopathological lung lesions.One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model.Pig-major acute phase protein and haptoglobin serum concentrations correlate with PCV2 viremia and the clinical course of postweaning multisystemic wasting syndrome.Detection of neutralizing antibodies in postweaning multisystemic wasting syndrome (PMWS)-affected and non-PMWS-affected pigs.Infectious risk factors for individual postweaning multisystemic wasting syndrome (PMWS) development in pigs from affected farms in Spain and Denmark.Infection, excretion and seroconversion dynamics of porcine circovirus type 2 (PCV2) in pigs from post-weaning multisystemic wasting syndrome (PMWS) affected farms in Spain and Denmark.When is the best time to vaccinate piglets against Mycoplasma hyopneumoniae.Humoral response and colostral antibody transfer following 'one-dose' pre-mating vaccination of sows against porcine circovirus type-2.
P50
Q33786775-89337885-9693-4C33-A780-052A438E882BQ35209214-4537154B-2D5D-4418-9340-89F31013D165Q36336177-7C39F72B-2EC9-43B2-80DF-B037CEE0F659Q36982900-1BB325BA-1C9A-4794-B614-FA0A23DFDC9DQ37132163-A7441D08-5643-464B-BB6F-760F5E1975C7Q37470430-28C46EC9-03F7-44CF-810A-4B39ECCBAA0AQ38352969-011F4928-E8EA-4134-8E3A-ACCE9410C53FQ38662206-69C3AA51-37AF-46D5-ABEA-87C21087E8E1Q38698824-664C8A21-8A99-487C-808E-89560E685E59Q38903870-060FBFA1-8FD2-4EB4-A038-69273C1B2BE1Q40082569-2993E5D2-BD92-4990-99CB-A127D3F099D1Q40682022-715B0685-BBBD-40AD-81C9-7CD0F53FF0BDQ40683805-4710A602-F25F-44DE-A051-706C626A1D15Q41445104-5911CAD1-19E3-44A2-84D0-F47CB00E5643Q41634775-A0A414FE-AD7F-45EF-B73B-99472DC752A5Q42022418-0AFF9746-C52C-4E8F-A274-17C2DE98075BQ42212590-A1256A2F-BB92-4037-9CB9-ACE89E108EEDQ42213853-277C70DF-F038-4F2D-92AF-A98B8EAE2FDDQ42843977-87E558FA-5F7D-424C-8648-C8D45C168447Q42996926-87C611E3-F260-4CB8-85CD-DCB69E0ADFB8Q43506132-F58BC541-05CB-4E23-ACD7-1C286D8C4479Q44194739-798F777A-83BC-4902-A7CB-BA405CEC33B7Q44813551-650F23EE-AE5D-4338-80D2-7BCA9004CFEBQ44964404-FB2BC7BE-08A6-4994-BDB6-1D149CE1FF80Q45124023-F0987E32-17B6-4E31-B45D-CCAE0866485EQ45358655-0A966EEB-A05A-4449-BC99-7148B7C90F7BQ45360911-1F0147A9-ED2B-4FA4-B0AC-7F112321F30EQ45386721-41C02AB8-DB58-4254-8EB8-C51768886407Q45390572-FBDB0AE6-0F47-421F-9712-D32EAFAC4667Q45412475-B2B00B4C-211D-4D53-9C62-3C8F0A1A852BQ47690758-082D57B0-9BBE-401C-880E-B7EF21692847Q47729768-DBCB4BFA-375F-46FE-AD5E-930724550FB3Q47948682-792639FC-782A-49D9-ACD6-748E83CF2EDDQ47979046-7BBD70E7-354B-4BAA-82BD-A9F80B8DB348Q48030182-22C8FA7E-D371-44BD-9DA7-D62B4BDB4974Q48078507-E3948750-9C4A-4566-A8D6-4D4370792C5FQ50025221-2937DCE7-75CB-4E34-B100-2D8FF5EA79C5Q50548637-01734CD3-0368-4B56-A37E-5305DF01CAE4Q50551426-FF849A10-1C32-489F-BA38-EBB4E8583B80Q50961579-52F34CD0-48AD-412B-92E6-BB5C45178A94
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marina Sibila
@ast
Marina Sibila
@en
Marina Sibila
@es
Marina Sibila
@nl
Marina Sibila
@sl
type
label
Marina Sibila
@ast
Marina Sibila
@en
Marina Sibila
@es
Marina Sibila
@nl
Marina Sibila
@sl
prefLabel
Marina Sibila
@ast
Marina Sibila
@en
Marina Sibila
@es
Marina Sibila
@nl
Marina Sibila
@sl
P106
P21
P31
P496
0000-0003-3867-1988